Sallie Mae Hovers Near $22 Ahead of Major Loan Test

Sallie Mae Hovers Near $22 Ahead of Major Loan Test

June 3, 2026

NEW YORK, June 3, 2026, 09:04 EDT

  • SLM was quoted at $22.05, little changed, ahead of the Nasdaq open.
  • Sallie Mae Fund expanded its scholarships for graduate students on June 2, the latest company move.
  • The stock is active before a June 4 record date tied to a $0.13 common dividend.

SLM Corp. stock hovered near $22.05 in premarket trading Wednesday, with little move as investors got no new jolt from earnings. Focus stayed on the company’s push in graduate loans, the timing for its dividend, and credit conditions. The Nasdaq operated on a regular schedule—June 3 is not a market holiday in 2026, per .

Sallie Mae is in focus now as private student-loan demand and consumer credit quality both remain hot topics. U.S. futures were divided early Wednesday—S&P 500 and Dow futures pointed lower, but Nasdaq 100 futures saw small gains. Smaller financials didn’t get much support from the market backdrop.

Sallie Mae Fund bumps up its Bridging the Dream Scholarship for Graduate Students to 20 awards at $10,000 each, according to a June 2 announcement. It also has 50 new Completing the Dream scholarships of up to $2,500. The application window is open until July 17.

Sallie Mae executive vice president Nic Jafarieh said in a release that as more students go on to graduate school to move up in their jobs and fill workforce gaps, scholarships matter more. Thurgood Marshall College Fund president and CEO Dr. Harry L. Williams said the programs deliver the support and resources students need to keep going in their education.

Scholarship announcements come as policy shifts shape up. The U.S. Department of Education said loan changes in the One Big Beautiful Bill Act will cut the Grad PLUS program and, starting July 2026, set yearly loan limits for new grad borrowers at $20,500 and pros at $50,000. That could push more borrowers to look at private lenders, but it doesn’t guarantee them more profit.

Sallie Mae took similar steps earlier. In May, it opened up graduate and law-school loans that can now cover up to 100% of school-certified attendance costs, according to Patrick Freeman, senior vice president at Sallie Mae. Freeman said students going for advanced degrees need a financing partner as they deal with changes to federal student-loan programs.

SLM’s loan growth came in higher this quarter. Private Education Loan originations climbed to $2.91 billion for the first quarter, compared with $2.77 billion a year ago. Graduate loans made up $217.7 million of that total. The company said 94.7% of those loans included a cosigner.

Margins still matter. Net interest margin came in at 5.29% in the first quarter, up 2 basis points over last year. Net interest income held steady at $375 million. The margin, which shows the gap between what the lender earns from assets and what it pays to fund them, remains in focus.

Sallie Mae has a near-term dividend coming up that could keep some income funds locked on the stock. The company set a second-quarter common dividend at $0.13 a share, with the payout slated for June 15 to holders on record at the close June 4.

Student finance and consumer loan stocks lost ground early. SoFi Technologies dropped 4.6%. Navient slipped 4.4%. Nelnet was steady. SLM showed almost no change.

But the risk is clear. SLM’s credit loss provision in Q1 got a $120 million lift from negative provisions linked to $3.33 billion of Private Education Loan sales. Charge-offs jumped to $102.8 million from $86.9 million. That protection could disappear fast if delinquencies, funding costs or the outlook get worse.

Right now, the stock trades closer to a low-multiple lender than a new policy favorite. The clearer test ahead: Will private graduate loan demand hold up without credit getting worse, and can SLM keep margins stable as funding costs and borrower pressure shift?

Konrad Wysocki

Konrad Wysocki is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Rzeszów, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • Clinuvel Pharmaceuticals (ASX:CUV) lists on Nasdaq as CUVL, pushes ahead on vitiligo study
    July 27, 2026, 5:35 AM EDT. Clinuvel Pharmaceuticals (ASX:CUV) started trading its American Depositary Shares on the Nasdaq Global Select Market as CUVL in July 2026, moving up from OTC ADRs. The company didn't issue shares or raise money with the move. Clinuvel reported FY2025 revenue of A$105.3 million, a 10% increase, with a net profit of A$36.2 million and cash at A$224.1 million, as sales of its SCENESSE treatment for erythropoietic protoporphyria (EPP) continued to drive results. The biotech is running a Phase III trial for vitiligo, with data expected late 2026, as it looks to move beyond its single drug. The Nasdaq launch aims to give Clinuvel more visibility in the US, though the company still faces clinical and regulatory hurdles.